ArticleChemistry (Weinheim an der Bergstrasse, Germany)2026
Stafib-2-CR: an Improved Nanomolar and Selective Inhibitor of the Transcription Factor STAT5b Developed by Conformational Restriction of Stafib-2.
Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fusion Molecules Between the STAT5b Inhibitor Stafib-2-CR and a Cereblon Ligand.ChemistryOpen · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The highly homologous transcription factors STAT5a and STAT5b are overactivated in many human tumor types. We recently reported catechol bisphosphates as the first chemical entities that inhibit STAT5b with selectivity over STAT5a. Here, we apply conformational restriction strategies to increase the activity and selectivity of Stafib-2, the most potent STAT5b inhibitor reported to date. The best conformationally restricted Stafib-2 analogue 8b (dubbed Stafib-2-CR) displayed approximately threefold higher activity against STAT5b than Stafib-2, associated with higher selectivity over STAT5a. Its cell-permeable prodrug 17 (dubbed Pomstafib-2-CR) inhibits phosphorylation of STAT5b in cultured human leukemia cells with slightly higher activity and selectivity over STAT5a than Pomstafib-2, the prodrug corresponding to Stafib-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.